These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 22024821)

  • 1. Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection.
    Sugaya N; Kohno S; Ishibashi T; Wajima T; Takahashi T
    Antimicrob Agents Chemother; 2012 Jan; 56(1):369-77. PubMed ID: 22024821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and safety of intravenous peramivir, neuraminidase inhibitor of influenza virus, in healthy Japanese subjects.
    Saisho Y; Ishibashi T; Fukuyama H; Fukase H; Shimada J
    Antivir Ther; 2017; 22(4):313-323. PubMed ID: 27805571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influenza viral load and peramivir kinetics after single administration and proposal of regimens for peramivir administration against resistant variants.
    Sato M; Ito M; Suzuki S; Sakuma H; Takeyama A; Oda S; Watanabe M; Hashimoto K; Miyazaki K; Kawasaki Y; Hosoya M
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1643-9. PubMed ID: 25547357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients.
    Kohno S; Kida H; Mizuguchi M; Hirotsu N; Ishida T; Kadota J; Shimada J;
    Antimicrob Agents Chemother; 2011 Jun; 55(6):2803-12. PubMed ID: 21464252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor.
    Sugaya N; Sakai-Tagawa Y; Bamba M; Yasuhara R; Yamazaki M; Kawakami C; Yamaguchi Y; Ide Y; Ichikawa M; Mitamura K; Kawaoka Y
    Antivir Ther; 2015; 20(1):49-55. PubMed ID: 24832015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peramivir for the treatment of influenza.
    Shetty AK; Peek LA
    Expert Rev Anti Infect Ther; 2012 Feb; 10(2):123-43. PubMed ID: 22339187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical effectiveness of neuraminidase inhibitors--oseltamivir, zanamivir, laninamivir, and peramivir--for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan.
    Shobugawa Y; Saito R; Sato I; Kawashima T; Dapat C; Dapat IC; Kondo H; Suzuki Y; Saito K; Suzuki H
    J Infect Chemother; 2012 Dec; 18(6):858-64. PubMed ID: 22644080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of clinical pharmacology in supporting the emergency use authorization of an unapproved anti-influenza drug, peramivir.
    Arya V; Carter WW; Robertson SM
    Clin Pharmacol Ther; 2010 Nov; 88(5):587-9. PubMed ID: 20959843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.
    Dapat C; Kondo H; Dapat IC; Baranovich T; Suzuki Y; Shobugawa Y; Saito K; Saito R; Suzuki H
    Antiviral Res; 2013 Sep; 99(3):261-9. PubMed ID: 23791870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of intravenous peramivir for treatment of severe influenza A(H1N1)pdm09.
    Louie JK; Yang S; Yen C; Acosta M; Schechter R; Uyeki TM
    PLoS One; 2012; 7(6):e40261. PubMed ID: 22768265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the binding affinities of peramivir and oseltamivir carboxylate to the neuraminidase enzyme.
    Bantia S; Upshaw R; Babu YS
    Antiviral Res; 2011 Sep; 91(3):288-91. PubMed ID: 21722670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postpartum pharmacokinetics of peramivir in the treatment of 2009 H1N1 influenza.
    Clay PG; Adiga RB; Taylor TAH; Alsup R; Gerk PM; McRae M
    Obstet Gynecol; 2011 Aug; 118(2 Pt 2):463-467. PubMed ID: 21768855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States.
    Hernandez JE; Adiga R; Armstrong R; Bazan J; Bonilla H; Bradley J; Dretler R; Ison MG; Mangino JE; Maroushek S; Shetty AK; Wald A; Ziebold C; Elder J; Hollister AS; Sheridan W;
    Clin Infect Dis; 2011 Mar; 52(6):695-706. PubMed ID: 21367722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peramivir and its use in H1N1 influenza.
    Castillo R; Holland LE; Boltz DA
    Drugs Today (Barc); 2010 Jun; 46(6):399-408. PubMed ID: 20571608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-marketing safety and effectiveness evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir. II: a pediatric drug use investigation.
    Komeda T; Ishii S; Itoh Y; Ariyasu Y; Sanekata M; Yoshikawa T; Shimada J
    J Infect Chemother; 2015 Mar; 21(3):194-201. PubMed ID: 25523716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice.
    Tarbet EB; Maekawa M; Furuta Y; Babu YS; Morrey JD; Smee DF
    Antiviral Res; 2012 Apr; 94(1):103-10. PubMed ID: 22429564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peramivir pharmacokinetics in a patient receiving continuous veno-venous hemodiafiltration during the 2009 H1N1 influenza A pandemic.
    Bentley ML; Hollistera AS; Hansenb AC; Smith JA; Cain JS
    Int J Clin Pharmacol Ther; 2014 Dec; 52(12):1105-11. PubMed ID: 25345428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus.
    Pizzorno A; Abed Y; Bouhy X; Beaulieu E; Mallett C; Russell R; Boivin G
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1208-14. PubMed ID: 22203589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peramivir pharmacokinetics in two critically ill adults with 2009 H1N1 influenza A concurrently receiving continuous renal replacement therapy.
    Bazan JA; Bauer KA; Hollister AS; Shidham G; Firstenberg MS; Reed EE; Mangino JE; Goff DA
    Pharmacotherapy; 2010 Oct; 30(10):1016-20. PubMed ID: 20874039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peramivir use for treatment of hospitalized patients with influenza A(H1N1)pdm09 under emergency use authorization, October 2009-June 2010.
    Yu Y; Garg S; Yu PA; Kim HJ; Patel A; Merlin T; Redd S; Uyeki TM
    Clin Infect Dis; 2012 Jul; 55(1):8-15. PubMed ID: 22491506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.